Beese Fulmer Investment Management 13F: New $514K Stake in GILD

Beese Fulmer Investment Management opened a new position in Gilead Sciences, Inc. GILD, acquiring 3,450 shares valued at about $514,181 in a Form 13F filing filed with the SEC on October 23, 2026. Institutional investors use Form 13F filings to report their stock holdings at the end of each quarter, giving markets a look at where professional money managers are placing their bets.

GILD Gilead Sciences, Inc.

$156.69 ▲ +31.18% year to date

1M 3M YTD

Daily close · Oct 23, 2026

What Changed in Beese Fulmer Investment Management's Gilead Sciences Position

Beese Fulmer Investment Management initiated a brand-new stake in the biopharmaceutical firm during the quarter, picking up 3,450 shares. The reported value of the holding reached $514,181 on the filing date.

Other Institutional Activity in Gilead Sciences

Other large investors adjusted their holdings in the stock around the same time. RMR Wealth Builders grew its holdings by 3,730 shares, ending with 42,950 shares worth about $6,401,721. Royal Fund Management raised its holdings by 21,288 shares, reaching 23,861 shares worth about $3,565,85. AMF Tjanstepension reduced its stake by 521,261 shares, ending with 21,001 shares valued at about $3,130,199. Quilter cut its position by 4,283 shares to finish with 25,109 shares worth about $3,742,497. CWA Asset Management Group grew its holdings by 15,240 shares, holding 78,639 shares worth about $11,721,086.

Gilead Sciences, Inc. Stock Up 1.6%

Gilead Sciences, Inc. GILD shares closed at $156.04 on October 23, 2026, and recently traded at $156.04 as of October 24, 2026. The stock trades above its 50-day moving average of $148.48 and sits well above its 200-day moving average of $138.71. Shares trade below the 52-week high of $160.51 and well above the 52-week low of $114.02.

Recent Earnings

Gilead Sciences, Inc. GILD reported trailing twelve-month revenue of $30.46 billion. The company posts no meaningful P/E ratio because it carries a negative trailing earnings per share of $2.65, alongside a net profit margin of -10.6% and a return on equity of -20.7%. Investors look ahead to the next earnings release scheduled for October 29, 2026.

Dividend

Gilead Sciences, Inc. GILD pays an annual dividend rate of $3.28 per share, which translates to a dividend yield of 2.09%.

Insider Buying and Selling at Gilead Sciences, Inc.

Company insiders completed several transactions ahead of the filing.

Analysts Set New Price Targets

Wall Street research firms updated their views on the stock through October.

About Gilead Sciences

Gilead Sciences, Inc. discovers, develops, and commercializes medicines for severe medical conditions in the United States and internationally, focusing heavily on antiviral treatments like therapies for HIV infections.

Bottom Line

Institutional interest in Gilead Sciences, Inc. remains active as market participants weigh recent price gains against upcoming financial results. Investors will watch the company's next earnings report on October 29, 2026, for further updates on its financial trajectory.